erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
Antineoplastic Combined Chemotherapy Protocols
Gene Expression Regulation, Neoplastic
Tumor Suppressor Protein p53
The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation. Interactions between erbB-2 expression, p53 expression, and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome.